Literature DB >> 24018504

Rhombencephalitis by Listeria monocytogenes in a cirrhotic patient: a case report and literature review.

Raúl Carrillo-Esper1, Luis Daniel Carrillo-Cordova, Isis Espinoza de los Monteros-Estrada, Agustín Omar Rosales-Gutiérrez, Misael Uribe, Nahum Méndez-Sánchez.   

Abstract

We report a case of rhombencephalitis infection by Listeria monocytogenes in a 66-year-old man with cirrhosis. The CSF analysis indicated L. monocytogenes as the most likely pathogen. Blood and CSF culture were positive to L. monocytogenes and MRI findings were suggestive of rhomboencephalitis. The treatment was started empirically and then modified when the culture results were available. The patient had a full clinical recovery without neurologic sequelae. Clinicians should remember that L. monocytogenes most often presents as acute bacterial meningitis, particularly in the elderly, the immunosuppressed, and those with malignancies. L. monocytogenes CNS the infections may present as acute bacterial meningitis, meningoencephalitis, or acute encephalitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24018504

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  2 in total

Review 1.  Early trigeminal nerve involvement in Listeria monocytogenes rhombencephalitis: case series and systematic review.

Authors:  William K Karlsson; Zitta Barrella Harboe; Casper Roed; Jeppe B Monrad; Mette Lindelof; Vibeke Andrée Larsen; Daniel Kondziella
Journal:  J Neurol       Date:  2017-07-20       Impact factor: 4.849

2.  The clinical features, diagnosis, treatment, and prognosis of neuroinvasive listeriosis: a multinational study.

Authors:  F Arslan; E Meynet; M Sunbul; O R Sipahi; B Kurtaran; S Kaya; A C Inkaya; P Pagliano; G Sengoz; A Batirel; B Kayaaslan; O Yıldız; T Güven; N Türker; I Midi; E Parlak; S Tosun; S Erol; A Inan; N Oztoprak; I Balkan; Y Aksoy; B Ceylan; M Yılmaz; A Mert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-20       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.